RCT1100-102 https://validator.w3.org/feed/docs/rss2.html The interplay of quaternary ammonium lipid structure and protein corona on lung-specific mRNA delivery by selective organ targeting (SORT) nanoparticles Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles Senior/Executive Director, Translational Sciences & Nonclinical Operations ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis ReCode Therapeutics to Participate in May Conferences ReCode Therapeutics to Participate in February Conferences Senior Scientist / Principal Scientist, Cell Biology – Lung Epithelia Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis New Article Published in Science Highlights the Potential of ReCode Therapeutics’ Systemic Lung Delivery and CFTR Gene Correction ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of its Board of Directors Scientist II, Chemistry Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing Fierce Biotech Names ReCode Therapeutics as One of its “Fierce 15” Biotech Companies of 2022 A Phase 1b Open-Label Study to Assess RCT1100 in DNAI-1 PCD Patients Rescue of Ciliary Function in Cell-based Primary Ciliary Dyskinesia Models using Nebulized, LNP-formulated mRNA ReCode Therapeutics to Present at 2022 RBC Capital Markets Global Healthcare Conference ReCode Therapeutics to Present Preclinical Data Using Proprietary SORT LNP Delivery Platform from its mRNA-based Therapeutic Programs at the ATS 2022 International Conference in San Francisco ReCode Therapeutics Corporate Presentation Optimization of DNAI1 mRNA Constructs to Treat Primary Ciliary Dyskinesia ReCode Therapeutics Announces Closing of Extension to Series B Financing ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia Aerosolized Therapy Restores CFTR in Patient-derived Cells Scientist II, Gene Editing ReCode Therapeutics to Present at September Investor Conferences Recode Therapeutics Appoints Erica Jefferson as Senior Vice President of Corporate Affairs Unshackling genetic medicines by enabling delivery beyond the liver ReCode Therapeutics to Present at Oppenheimer 32nd Annual Healthcare Conference Seven technologies to watch in 2022 ReCode Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer An mRNA-Based Therapy to Treat Primary Ciliary Dyskinesia: Aerosol Delivery, Biodistribution and Tolerability Functional Rescue of CFTR by Aerosolized Delivery of Optimized CFTR mRNA Using ReCode LNPs in Primary Human Bronchial Epithelial Cells Derived From Patients With Cystic Fibrosis Pfizer, Sanofi-backed LNP outfit goes back to the well and draws $120M for its trek to the clinic ReCode Therapeutics Presents Preclinical Data from Inhaled mRNA Therapeutic Program in Primary Ciliary Dyskinesia (PCD) in Three Posters at the ATS 2022 International Conference ReCode Therapeutics Presents New Preclinical Data from mRNA-based Program for Cystic Fibrosis at the ATS 2022 International Conference ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M ReCode Raises Another $120m To Broaden LNP Delivery Of Genetic Medicines ReCode breaks the mold with $120M financing, bringing clutch of Big Pharmas along for ride ReCode Therapeutics to Participate in Upcoming July Investor Conferences SORTing It Out: ReCode Expands Beyond Respiratory Disorders Peninsula company raises $120M to build new vehicles for mRNA drugs, other therapies ReCode Therapeutics Raises $200M in Series B ReCode Therapeutics to Participate in Upcoming October Investor Conferences Cookie Policy ReCode Therapeutics to Present at Jefferies Cell and Genetic Medicine Summit ReCode Therapeutics to Participate in November Conferences ReCode Therapeutics to Present at Jefferies Healthcare Conference